Avecho Biotechnology Ltd - Asset Resilience Ratio
Avecho Biotechnology Ltd (AVE) has an Asset Resilience Ratio of 82.51% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Avecho Biotechnology Ltd's Asset Resilience Ratio has changed over time. Check Avecho Biotechnology Ltd (AVE) strategic asset index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Avecho Biotechnology Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AVE company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.93 Million | 82.51% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$5.93 Million | 82.51% |
Asset Resilience Insights
- Very High Liquidity: Avecho Biotechnology Ltd maintains exceptional liquid asset reserves at 82.51% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Avecho Biotechnology Ltd Industry Peers by Asset Resilience Ratio
Compare Avecho Biotechnology Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 10.93% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
TELIX Pharmaceuticals Ltd
AU:TLX |
Biotechnology | 32.29% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 2.34% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
Annual Asset Resilience Ratio for Avecho Biotechnology Ltd (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Avecho Biotechnology Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 47.52% | AU$2.37 Million ≈ $1.68 Million |
AU$5.00 Million ≈ $3.54 Million |
+47.31pp |
| 2023-12-31 | 0.21% | AU$15.73K ≈ $11.13K |
AU$7.32 Million ≈ $5.18 Million |
-46.23pp |
| 2022-12-31 | 46.45% | AU$1.55 Million ≈ $1.10 Million |
AU$3.35 Million ≈ $2.37 Million |
-15.79pp |
| 2021-12-31 | 62.23% | AU$3.26 Million ≈ $2.31 Million |
AU$5.25 Million ≈ $3.71 Million |
+6.41pp |
| 2020-12-31 | 55.83% | AU$1.87 Million ≈ $1.33 Million |
AU$3.35 Million ≈ $2.37 Million |
-4.58pp |
| 2019-12-31 | 60.40% | AU$3.21 Million ≈ $2.27 Million |
AU$5.32 Million ≈ $3.76 Million |
+15.26pp |
| 2018-12-31 | 45.15% | AU$2.17 Million ≈ $1.53 Million |
AU$4.80 Million ≈ $3.40 Million |
+4.45pp |
| 2017-12-31 | 40.70% | AU$3.35 Million ≈ $2.37 Million |
AU$8.24 Million ≈ $5.83 Million |
+39.16pp |
| 2016-12-31 | 1.54% | AU$205.00K ≈ $145.05K |
AU$13.35 Million ≈ $9.45 Million |
+1.49pp |
| 2003-12-31 | 0.05% | AU$13.78K ≈ $9.75K |
AU$29.41 Million ≈ $20.81 Million |
+0.05pp |
| 2002-12-31 | 0.00% | AU$-429.00 ≈ $-303.54 |
AU$14.84 Million ≈ $10.50 Million |
-1.31pp |
| 2001-12-31 | 1.30% | AU$240.00K ≈ $169.82K |
AU$18.40 Million ≈ $13.02 Million |
-0.61pp |
| 2000-12-31 | 1.92% | AU$400.00K ≈ $283.03K |
AU$20.86 Million ≈ $14.76 Million |
+1.34pp |
| 1999-12-31 | 0.58% | AU$29.44K ≈ $20.83K |
AU$5.10 Million ≈ $3.61 Million |
+0.58pp |
| 1996-12-31 | 0.00% | AU$-499.00 ≈ $-353.07 |
AU$33.01 Million ≈ $23.36 Million |
-84.53pp |
| 1993-12-31 | 84.53% | AU$10.04 Million ≈ $7.10 Million |
AU$11.88 Million ≈ $8.40 Million |
-- |
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more